Sierra’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more

Stephen Dilly's photo - President & CEO of Sierra

President & CEO

Stephen Dilly

CEO Approval Rating

90/100

Founded:

2003

Status:

PublicNASDAQSRRA

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Incyte has been one of Sierra's top competitors. Incyte's headquarters is in Wilmington, Delaware, and was founded in 1991. Incyte is in the Pharmaceuticals industry. Incyte generates ∞% of Sierra's revenue.

Novartis is one of Sierra's top rivals. Novartis is a Public company that was founded in Basel, Basel-City in 1996. Novartis operates in the Pharmaceuticals industry. Novartis has 103,843 more employees vs. Sierra.

Celgene is perceived as one of Sierra's biggest rivals. Celgene was founded in 1986, and is headquartered in Summit, New Jersey. Celgene operates in the Biotechnology industry. Celgene generates $15.3B more revenue vs. Sierra.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Sierra?

Quarterly and Annual Revenue

Coming soon for Sierra!

Annual Revenue

Acquisitions

No recent acquisitions found related to Sierra

Investments

No recent investments found related to Sierra

Sierra News

June 18, 2020Zacks

What Does It Mean for the Stock?

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which... See more »
June 12, 2020MarketScreener

Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

(marketscreener.com) - Data presented at the 25th European Hematology Association Virtual Congress fu... See more »
May 27, 2020MarketScreener

Announces Presentations at Upcoming Investor Conferences

(marketscreener.com) - Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 2... See more »
May 7, 2020BioSpace

Sierra Oncology Reports First Quarter 2020 Results

Sierra Oncology, Inc. (SRRA), today reported its financial and operational results for the first quar... See more »
March 12, 2020FierceBiotech

Attacking drug-resistant tumors with Sierra's struggling CHK1 blocker

Sierra Oncology deprioritized the development of its CHK1 blocker SRA737 last year, as it steered mos... See more »
March 6, 2020Themarketsdaily

Q1 2020 Earnings Estimate for Sierra Oncology Inc (NASDAQ:SRRA) Issued By Oppenheimer

Sierra Oncology Inc (NASDAQ:SRRA) – Oppenheimer lowered their Q1 2020 earnings per share (EPS) estima... See more »

Sierra Press Releases

December 7, 2019centralcharts

Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Dire... See more »
December 2, 2019PR Newswire

Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8... See more »
November 6, 2019PR Newswire

Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019

- New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients a... See more »
August 7, 2019centralcharts

Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

VANCOUVER, Aug. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development co... See more »
June 27, 2019PR Newswire

Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Explorin... See more »
June 1, 2019CentralCharts

Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration

- Sierra to discuss clinical findings and possible next steps for SRA737 at Analyst & Investor Event ... See more »
May 15, 2019PR Newswire

Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster prese... See more »

Headquarters

885 West Georgia Street Suite 2150

Vancouver, British ColumbiaV6C 3E8

604-558-6536

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Sierra was founded in 2003. Sierra's headquarters is located in Vancouver, British Columbia, CA V6C 3E8. Sierra...

CEO

Sierra's President & CEO, Stephen Dilly, currently has an approval rating of 90%. Sierra's primary competitors are Incyte, Novartis & Celgene.

Website

sierraoncology.com

Frequently Asked Questions about Sierra

  1. When was Sierra founded?

    Sierra was founded in 2003
  2. Who is Sierra's CEO?

    Sierra's CEO is Stephen Dilly
  3. How much revenue does Sierra generate?

    Sierra generates $ < 1M in revenue
  4. How much funding does Sierra have?

    Sierra has historically raised $0 in funding
  1. Where is Sierra's headquarters?

    Sierra's headquarters is in Vancouver British Columbia, CA
  2. How many employees does Sierra have?

    Sierra has 71 employees
  3. What sector does Sierra operate in?

    Sierra is in Health Care Services
  4. Who are Sierra's competitors?

    Sierra's top competitors are Incyte, Novartis, Celgene